MCID: BNR002
MIFTS: 47

Bone Resorption Disease

Categories: Bone diseases

Aliases & Classifications for Bone Resorption Disease

MalaCards integrated aliases for Bone Resorption Disease:

Name: Bone Resorption Disease 12 15
Bone Resorption 44

Classifications:



External Ids:

Disease Ontology 12 DOID:0080011
MeSH 44 D001862

Summaries for Bone Resorption Disease

Disease Ontology : 12 A bone remodeling disease that results in an abnormal decrease of bone density or mass.

MalaCards based summary : Bone Resorption Disease, also known as bone resorption, is related to osteopetrosis and osteitis fibrosa. An important gene associated with Bone Resorption Disease is BGLAP (Bone Gamma-Carboxyglutamate Protein), and among its related pathways/superpathways are MicroRNAs in cancer and RANK Signaling in Osteoclasts. The drugs Denosumab and Alendronate have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and bone marrow, and related phenotypes are cellular and craniofacial

Wikipedia : 74 Bone resorption is resorption of bone tissue, that is, the process by which osteoclasts break down the... more...

Related Diseases for Bone Resorption Disease

Diseases related to Bone Resorption Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 443)
# Related Disease Score Top Affiliating Genes
1 osteopetrosis 32.5 TNFSF11 RUNX2 NFATC1 LRP5 CTSK CALCA
2 osteitis fibrosa 32.4 PTH CALCA BGLAP
3 multicentric carpotarsal osteolysis syndrome 32.4 TNFSF11 CTSK BGLAP ACP5
4 pycnodysostosis 32.4 TNFSF11 SOST CTSK ACP5
5 paget's disease of bone 32.4 TNFSF11 SOST PTH CALCA BGLAP ACP5
6 bone giant cell tumor 32.3 TNFSF11 PTH CTSK CALCA ACP5
7 paget disease of bone 5, juvenile-onset 32.2 TNFSF11 CALCA
8 glucocorticoid-induced osteoporosis 32.2 TNFSF11 RUNX2 PTH IGF1 CALCA BMP2
9 periodontitis 32.1 TNFSF11 RUNX2 CTSK BGLAP ACP5
10 hyperparathyroidism 31.7 TNFSF11 PTH CALCA BGLAP ACP5
11 mammary paget's disease 31.6 TNFSF11 PTH ESR1 CALCA BGLAP ACP5
12 osteoporosis 31.6 TNFSF11 SP7 SOST RUNX2 PTH NFATC1
13 bone disease 31.6 TNFSF11 SP7 SOST RUNX2 PTH NFATC1
14 secondary hyperparathyroidism 31.4 PTH CALCA BGLAP ACP5
15 osteogenic sarcoma 31.4 TNFSF11 SP7 RUNX2 PTH MIR140 IGF1
16 bone remodeling disease 31.3 TNFSF11 SP7 SOST RUNX2 PTH NFATC1
17 primary hyperparathyroidism 31.3 TNFSF11 SOST PTH IGF1 CALCA BGLAP
18 benign giant cell tumor 31.2 TNFSF11 CTSK CALCA BGLAP
19 hyperthyroidism 31.2 PTH IGF1 CALCA BGLAP ACP5
20 chronic kidney disease 31.2 TNFSF11 SOST RUNX2 PTH IGF1 BGLAP
21 osteomalacia 31.2 SOST PTH CALCA BGLAP
22 insulin-like growth factor i 31.1 IGF1 ESR1 BGLAP
23 root resorption 31.1 TNFSF11 RUNX2 CTSK CALCA
24 osteonecrosis 31.1 TNFSF11 RUNX2 PTH NFATC1 LRP5 IGF1
25 renal osteodystrophy 31.1 TNFSF11 SOST PTH CALCA BGLAP
26 osteomyelitis 31.0 TNFSF11 NFATC1 CTSK CALCA BMP2 ACP5
27 hypercalcemia, infantile, 1 31.0 PTH CALCA
28 ankylosis 30.9 TNFSF11 SP7 RUNX2 BMP2 BGLAP
29 exostosis 30.8 SOST CALCA BMP2 BGLAP
30 hypoparathyroidism 30.8 PTH IGF1 CALCA BGLAP
31 hemiplegia 30.8 CALCA BGLAP ACP5
32 spondyloarthropathy 1 30.8 TNFSF11 PTH BGLAP
33 sclerosteosis 30.7 TNFSF11 SP7 SOST RUNX2 PTH LRP5
34 hypervitaminosis d 30.7 PTH CALCA
35 periapical periodontitis 30.7 TNFSF11 RUNX2 CTSK ACP5
36 bone cancer 30.6 TNFSF11 PTH MIR140 ESR1 CALCA BMP2
37 scoliosis 30.5 TNFSF11 RUNX2 IGF1 ESR1 CTSK BGLAP
38 brittle bone disorder 30.5 TNFSF11 SP7 SOST RUNX2 PTH LRP5
39 hyperphosphatemia 30.5 RUNX2 PTH BGLAP
40 fibrous dysplasia 30.5 TNFSF11 IGF1 CALCA BGLAP
41 bone inflammation disease 30.5 TNFSF11 MIR140 ACP5
42 spondylolisthesis 30.5 PTH ESR1 BMP2
43 camurati-engelmann disease 30.4 SP7 RUNX2 LRP5 BGLAP ACP5
44 breast adenocarcinoma 30.3 TNFSF11 ESR1 CTSK CALCA
45 microphthalmia 30.3 TNFSF11 NFATC1 LRP5 CTSK ACP5
46 ovarian disease 30.2 MIR23A MIR140 IGF1 ESR1
47 type 2 diabetes mellitus 30.2 TNFSF11 SOST RUNX2 LRP5 IGF1 ESR1
48 heart disease 30.1 NFATC1 MIR23A MIR214 MIR140 IGF1 ESR1
49 connective tissue disease 30.0 TNFSF11 SOST RUNX2 PTH MIR335 MIR23A
50 odontochondrodysplasia 30.0 TNFSF11 SP7 SOST RUNX2 PTH LRP5

Graphical network of the top 20 diseases related to Bone Resorption Disease:



Diseases related to Bone Resorption Disease

Symptoms & Phenotypes for Bone Resorption Disease

MGI Mouse Phenotypes related to Bone Resorption Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 BGLAP BMP2 CTSK ESR1 IGF1 LRP5
2 craniofacial MP:0005382 9.7 BMP2 CTSK LRP5 NFATC1 PTH RUNX2
3 limbs/digits/tail MP:0005371 9.7 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
4 skeleton MP:0005390 9.4 BGLAP BMP2 CTSK ESR1 IGF1 LRP5

Drugs & Therapeutics for Bone Resorption Disease

Drugs for Bone Resorption Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denosumab Approved Phase 4 615258-40-7
2
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
3
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
4
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
5 Hormones Phase 4
6 Calcium, Dietary Phase 4
7 Diphosphonates Phase 4
8 Ibandronic Acid Phase 4
9
Calcium Nutraceutical Phase 4 7440-70-2 271
10 Abaloparatide Approved, Investigational Phase 3 247062-33-5
11
Zoledronic Acid Approved Phase 3 118072-93-8 68740
12
Risedronate Approved, Investigational Phase 3 105462-24-6 5245
13 Anesthetics Phase 3
14 Liver Extracts Phase 2, Phase 3
15 glucocorticoids Phase 3
16
Parathyroid hormone Approved, Investigational Phase 1, Phase 2 9002-64-6
17
Pamidronate Approved Phase 2 40391-99-9 4674
18
nivolumab Approved Phase 1, Phase 2 946414-94-4
19
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
20
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
21
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 6221 5280795
22
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 1406-16-2
24
Saracatinib Investigational Phase 2 379231-04-6
25 Whey Protein Phase 1, Phase 2
26 Vitamin D2 Phase 2
27 Ergocalciferols Phase 2
28 Paraproteins Phase 1, Phase 2
29 Antineoplastic Agents, Immunological Phase 1, Phase 2
30 Interferon-gamma Phase 1, Phase 2
31 Myeloma Proteins Phase 1, Phase 2
32 interferons Phase 1, Phase 2
33 Immunoglobulins, Intravenous Phase 1, Phase 2
34 Immunoglobulins Phase 2
35 Antibodies Phase 2
36 Antibodies, Monoclonal Phase 2
37 Androgen Antagonists Phase 2
38 Androgens Phase 2
39 Nutrients Phase 1, Phase 2
40 Micronutrients Phase 1, Phase 2
41 Trace Elements Phase 1, Phase 2
42 Vitamins Phase 1, Phase 2
43 Calciferol Phase 1, Phase 2
44 Aromatase Inhibitors Phase 1, Phase 2
45 Soy Bean Phase 1
46
Povidone-iodine Approved 25655-41-8
47
Methamphetamine Approved, Illicit 537-46-2 10836
48
Dopamine Approved 51-61-6, 62-31-7 681
49
Chlorhexidine Approved, Vet_approved 55-56-1 9552079 2713
50
Amoxicillin Approved, Vet_approved 26787-78-0 33613

Interventional clinical trials:

(show top 50) (show all 110)
# Name Status NCT ID Phase Drugs
1 Bone Resorption, Osteoclastogenesis and Adalimumab Unknown status NCT02035800 Phase 4 Adalimumab
2 A Method for Measuring Volume Changes of the Alveolar Ridge During Dental Implantation Using 3D Scanning Unknown status NCT03089619 Phase 4 Human-Spongiosa
3 The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty: A Randomised, Double Blind, Placebo Controlled Clinical Trial Completed NCT02760979 Phase 4 Denosumab;Placebo
4 Evaluation of Anterior Alveolar Ridge Reconstruction With Allogenic Bone Plate and Autogenous Cortical Bone Chips: A Radiographic and Histological Clinical Study Completed NCT04324697 Phase 4
5 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
6 A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]
7 Effects of 1% Sodium Alendronate in Non Surgical Periodontal Therapy on Clinical and Tomographical Parameters: a Randomized Placebo Controlled 6-month Clinical Trial Completed NCT02470611 Phase 4 Sodium alendronate
8 Hyaluronic Acid Effect on Xenogenic Bone Substitutes Healing During Ridge Preservations: A Radiological and Histomorphometric Study Recruiting NCT04377256 Phase 4
9 An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 or Placebo Treatment in Protocol BA058-05-003 Completed NCT01657162 Phase 3 Alendronate
10 Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy Completed NCT00172055 Phase 3 Zoledronic acid
11 Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation Completed NCT00297830 Phase 2, Phase 3 Zoledronic acid;Alendronate
12 COMPARATIVE EVALUATION OF BIOACTIVE GLASS PUTTY AND PLATELET RICH FIBRIN IN THE TREATMENT OF HUMAN PERIODONTAL INTRABONY DEFECTS- A CLINICAL AND RADIOGRAPHICAL STUDY" Completed NCT02982681 Phase 3 Platelet rich fibrin;Bioactive Glass
13 Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial Not yet recruiting NCT04034199 Phase 3 Denosumab;Zoledronic Acid
14 A Randomized, Open-label Therapeutic Trial Evaluating the Efficacy and Safety of Neridronate (Nerixia®) in the Treatment of Osteoporosis in Patients With Thalassemia Major and Severe Thalassemia Intermedia. Completed NCT01140321 Phase 2 Neridronate
15 Impact of a Protein Supplement on Bone Mass in Older Men and Women Completed NCT00421408 Phase 1, Phase 2
16 Teh Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) Wif Alendronate in Teh Preservation of Teh Tooth Socket Completed NCT03980847 Phase 2 Alendronate 20 mg
17 Pilot Study to Evaluate the Effect of Zoledronic Acid (Zometa) on Occult Malignant Bone Marrow Cells in Patients With High Risk Early Stage Breast Cancer Completed NCT00295867 Phase 2 Zoledronic Acid
18 A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease. Completed NCT00558272 Phase 2 AZD0530;Zoledronic Acid
19 The Effect Of Lasofoxifene On Local Mediators Of Bone Resorption In The Prevention Of Postmenopausal Osteoporosis Completed NCT00674453 Phase 2 Lasofoxifene
20 Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005) Completed NCT00533650 Phase 2 MK0429
21 Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation Recruiting NCT02074631 Phase 2 Pamidronate;Calcium and vitamin D
22 Bone Quality and Quantity in the Maxillary Sinus Grafted With Xenograft or Synthetic Bone Substitute: A Radiographic and Histomorphometric Randomized Controlled Clinical Study Recruiting NCT04433117 Phase 2
23 A Randomized, Double-blind and Imitation, Parallel-control, Multicenter Phase II Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) With Bone Metastasis Recruiting NCT04325776 Phase 2 AL2846;Zoledronic Acid Injection
24 A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma Recruiting NCT03161756 Phase 1, Phase 2 Denosumab;Nivolumab;Ipilimumab
25 Feasibility of Bisphosphonate Use on Sleeve Gastrectomy Associated Bone Loss: Healthy Body, Healthy Bones Trial Recruiting NCT04279392 Phase 1, Phase 2 Zoledronic Acid 5 mg/Bag 100 ml Inj;Placebos
26 A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. Suspended NCT03869762 Phase 2 Xgeva;Xtandi
27 A Phase I/II Randomized, Double-blind, Controlled Study to Evaluate Efficacy and Safety of Vitamin D on Bone Mineral Density and Markers of Bone Resorption in Aromatase Inhibitor-induced Bone Loss in Women With Breast Cancer. Terminated NCT00904423 Phase 1, Phase 2 Vitamin D
28 Phase I Trial of Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Fully Human Monoclonal Antibody to RANKL (TK006) in Post-menopausal Women. Unknown status NCT03242512 Phase 1
29 Health of Young European Families and Fish Consumption Unknown status NCT00315770 Phase 1
30 Effect of Soy Bread on Markers of Bone Metabolism and Cardiovascular Disease Completed NCT00366860 Phase 1
31 Evaluation of Efficacy of Injectable Platelet-Rich Plasma (PRP) in Reducing Alveolar Bone Resorption Following Rapid Maxillary Expansion (RME): A Cone Beam Computed Tomography (CBCT) Assessment Completed NCT03028038 Phase 1 Platelet Rich Plasma;No Platelet Rich Plasma
32 A Double-Blind, Placebo-Controlled, Once-Weekly, Multiple-Dose Study to Investigate the Safety, Tolerability, Plasma Concentration Profile and Effects on Biochemical Markers of Bone Resorption of MK0822 in Healthy Postmenopausal Female Subjects Completed NCT00770159 Phase 1 odanacatib;Comparator: placebo to MK0822
33 Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial Recruiting NCT03173976 Phase 1 Zoledronic Acid
34 Alveolar Ridge Preservation in Mandibular Molars Using Mixture of Autogenous Bone & Anorganic Bovine Bone (ABB) Versus Anorganic Bovine Bone Alone Versus Absorbent Gelatin Sponge Unknown status NCT03584984
35 Clinical Assessment of Buccal Plate Expansion Technique Versus Guided Bone Regeneration Technique in Socket Preservation in The Esthetic Zone: A Randomized Controlled Clinical Trial Unknown status NCT03065803
36 Assessment of Vertical Bone Augmentation Using Autogenous Onlay Versus Inlay Grafting Techniques With Simultaneous Implant Placement in the Anterior Maxillary Area on Patient's Esthetic Satisfaction : A Randomized Clinical Trial Unknown status NCT03052387
37 Evaluation of Computer-Guided Versus Conventional Simultaneous Implant Placement With Ridge Augmentation Using an Autogenous Bone Ring Graft With PRF on Patient's Esthetic Satisfaction Unknown status NCT03049137 Platelet-rich fibrin (PRF)
38 Posterior Maxillary Ridge Augmentation With Sinus Lift Using Mineralized Plasmatic Matrix Versus Autogenous Bone Graft (A Randomized Clinical Trial Comparative Study) Unknown status NCT03014388
39 Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial Unknown status NCT03212820
40 Implant Insertion in Defective Anterior Maxillary Ridge Augmented Using Mineralized Plasmatic Matrix Versus Autogenous Bone Graft Unknown status NCT03007069
41 A Prospective, Randomized-controlled Study of the Effect of a Chlorhexidine Based Gel on the Internal Implant Surface Treatment on the Reduction of Bacterial Load and on the Regressive Bone Modelling. Unknown status NCT03431766
42 Clinical Evaluation Of Dental Implants Stability Placed In Healed Bony Sites Following Over-drilling Compared To Conventional-Drilling Protocol: A Randomized Controlled Trial. Unknown status NCT03250949
43 Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial Unknown status NCT03220815
44 Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial Unknown status NCT03220789
45 Role of Light Emitting Diode on Implant Stability, Bone Resorption and Analgesia Post Dental Implant Placement Unknown status NCT01097499
46 Immediate Dentoalveolar Restoration Compared to Demineralized Bovine Bone in Immediate Implants Placed in Fresh Sockets With Buccal Bone Resorption: 18-months Randomized Controlled Trial Unknown status NCT03202030
47 Influence of Superstructure Material on Crestal Bone Resorption and Esthetic Outcome of Dental Implants Unknown status NCT02937220
48 Socket Shield Technique Versus Conventional Immediate Implant Placement in Thin Buccofacial Bone to Evaluate Buccal Bone Resorption: A Randomized Controlled Trial Unknown status NCT03264053
49 Standard Implants With Bone Regeneration vs Short Implants (Implantes Convencionales Con regeneración ósea vs. Implantes Cortos) Unknown status NCT03524885
50 Alveolar Ridge Preservation In Mandibular Molars Using Mixture Of Anorganic Bovine Bone(ABB) And Autogenous Particulate VS Mixture Of Injectable Platelets Rich Fibrin, ABB And Autogenous Particulates (Sticky Bone). Unknown status NCT03584997

Search NIH Clinical Center for Bone Resorption Disease

Cochrane evidence based reviews: bone resorption

Genetic Tests for Bone Resorption Disease

Anatomical Context for Bone Resorption Disease

MalaCards organs/tissues related to Bone Resorption Disease:

40
Bone, Breast, Bone Marrow, Prostate, Kidney, Monocytes, Thyroid

Publications for Bone Resorption Disease

Articles related to Bone Resorption Disease:

(show top 50) (show all 25681)
# Title Authors PMID Year
1
Kaiso regulates osteoblast differentiation and mineralization via the Itga10/PI3K/AKT signaling pathway. 61
33576467 2021
2
Trem2 mediated Syk-dependent ROS amplification is essential for osteoclastogenesis in periodontitis microenvironment. 61
33486152 2021
3
A missense mutation sheds light on a novel structure-function relationship of RANKL. 61
32964459 2021
4
Trilobatin ameliorates bone loss via suppression of osteoclast cell differentiation and bone resorptive function in vitro and in vivo. 61
33497739 2021
5
Nano-needle strontium-substituted apatite coating enhances osteoporotic osseointegration through promoting osteogenesis and inhibiting osteoclastogenesis. 61
33102935 2021
6
Anti-perimenopausal osteoporosis effects of Erzhi formula via regulation of bone resorption through osteoclast differentiation: A network pharmacology-integrated experimental study. 61
33444724 2021
7
Schistosoma japonicum cystatin suppresses osteoclastogenesis via manipulating the NF‑κB signaling pathway. 61
33576450 2021
8
Hepatocyte growth factor overexpression promotes osteoclastogenesis and exacerbates bone loss in CIA mice. 61
33344167 2021
9
Effect of environmental tobacco smoke on COX-2 and SHP-2 expression in a periodontitis rat model. 61
32640491 2021
10
Vertebral pneumaticity is correlated with serial variation in vertebral shape in storks. 61
32981054 2021
11
Skeletal health in patients with differentiated thyroid carcinoma. 61
32696339 2021
12
Cortical and medullary morphology of the tibia. 61
32585072 2021
13
Serine/threonine phosphatases in osteoclastogenesis and bone resorption. 61
33338510 2021
14
Abaloparatide treatment increases bone formation, bone density and bone strength without increasing bone resorption in a rat model of hindlimb unloading. 61
33338664 2021
15
Effects of monthly intravenous ibandronate on bone mineral density and microstructure in patients with primary osteoporosis after teriparatide treatment: The MONUMENT study. 61
33249321 2021
16
Osteoclastogenesis and sphingosine-1-phosphate secretion from human osteoclast precursor monocytes are modulated by the cystic fibrosis transmembrane conductance regulator. 61
33188942 2021
17
Bisphosphonates and management of kidney stones and bone disease. 61
33394731 2021
18
Exosomes from TNF-α-treated human gingiva-derived MSCs enhance M2 macrophage polarization and inhibit periodontal bone loss. 61
33359765 2021
19
The effect of lipoxin A4 on E. coli LPS-induced osteoclastogenesis. 61
32506323 2021
20
Electrical stimulation of hindlimb skeletal muscle has beneficial effects on sublesional bone in a rat model of spinal cord injury. 61
33348128 2021
21
Evolution of bone mineral density in patients with idiopathic hypercalciuria: a 20-year longitudinal study. 61
32980941 2021
22
Liver X receptors and skeleton: Current state-of-knowledge. 61
33333244 2021
23
Cross-sectional analysis of spatial distribution and total amount of harvestable calvarian split bone. 61
33278578 2021
24
CXCL5, CXCL8, and CXCL10 regulation by bacteria and mechanical forces in periodontium. 61
33221386 2021
25
Carnosol suppresses RANKL-induced osteoclastogenesis and attenuates titanium particles-induced osteolysis. 61
32722851 2021
26
Inhibition of furin by bone targeting superparamagnetic iron oxide nanoparticles alleviated breast cancer bone metastasis. 61
33005833 2021
27
The Junctional Epithelium Is Maintained by a Stem Cell Population. 61
32985318 2021
28
Resorbable additively manufactured scaffold imparts dimensional stability to extraskeletally regenerated bone. 61
33493771 2021
29
RANKL as a key figure in bridging between the bone and immune system: Its physiological functions and potential as a pharmacological target. 61
32956720 2021
30
miRNAs in osteoclast biology. 61
33212320 2021
31
Active hematopoiesis triggers exosomal release of PRDX2 that promotes osteoclast formation. 61
33587325 2021
32
Bone remodeling in the longest living rodent, the naked mole-rat: Interelement variation and the effects of reproduction. 61
33554344 2021
33
Unraveling the mystery of Gaucher bone density pathophysiology. 61
32782168 2021
34
Influence of implant-specific radiation doses on peri-implant hard and soft tissue: An observational pilot study. 61
33278849 2021
35
Bone Morphogenetic Protein-2 Promotes Osteoclasts-mediated Osteolysis via Smad1 and p65 Signaling Pathways. 61
33156278 2021
36
Expression of osteoclastogenic and anti-osteoclastogenic cytokines differs in mouse gingiva injected with lipopolysaccharide, peptidoglycan, or both. 61
33259988 2021
37
PMEPA1 and NEDD4 control the proton production of osteoclasts by regulating vesicular trafficking. 61
33484199 2021
38
Mountain Bike Racing Stimulates Osteogenic Bone Signaling and Ingesting Carbohydrate-Protein Compared With Carbohydrate-Only Prevents Acute Recovery Bone Resorption Dominance. 61
33337693 2021
39
Association of RANK and RANKL gene polymorphism with survival and calcium levels in multiple myeloma. 61
33283899 2021
40
Clinical and satisfaction outcomes of using one or two dental implants for mandibular overdentures: preliminary short-term follow-up of a randomized clinical trial. 61
33569757 2021
41
Evaluation of the intaglio surface shape of implant-supported complete-arch maxillary prostheses and its association with biological complications: An analytical cross-sectional study. 61
33563467 2021
42
Design, synthesis, and evaluation of mono-carbonyl analogues of curcumin (MCACs) as potential antioxidants against periodontitis. 61
33604902 2021
43
Can Probiotics Emerge as Effective Therapeutic Agents in Apical Periodontitis? A Review. 61
33580864 2021
44
The Involvement of Histone Methylation in the Osteogenic Differentiation of Mesenchymal Stem Cells. 61
33563176 2021
45
Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained. 61
32916023 2021
46
PEG-Coated Large Mesoporous Silicas as Smart Platform for Protein Delivery and Their Use in a Collagen-Based Formulation for 3D Printing. 61
33572076 2021
47
Bone loss markers in the earliest Pacific Islanders. 61
33597553 2021
48
Partial deficiency of HIF-1α in chondrocytes effected bone repair of mandibular condylar neck. 61
33348208 2021
49
[Clinical study on early loading restoration of superhydrophilic implants]. 61
33557500 2021
50
A Case of Mandibular Prognathism with Generalized Aggressive Periodontitis and Crowding. 61
33583878 2021

Variations for Bone Resorption Disease

Expression for Bone Resorption Disease

Search GEO for disease gene expression data for Bone Resorption Disease.

Pathways for Bone Resorption Disease

GO Terms for Bone Resorption Disease

Cellular components related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.4 TNFSF11 SOST PTH MIR335 MIR23A MIR140

Biological processes related to Bone Resorption Disease according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.98 SOST RUNX2 NFATC1 LRP5 IGF1 ESR1
2 gene silencing by miRNA GO:0035195 9.97 MIR335 MIR23A MIR214 MIR188 MIR140 MIR133A1
3 positive regulation of gene expression GO:0010628 9.95 TNFSF11 RUNX2 MIR140 MIR133A1 IGF1 BMP2
4 positive regulation of transcription by RNA polymerase II GO:0045944 9.81 TNFSF11 SP7 RUNX2 PTH NFATC1 LRP5
5 negative regulation of gene expression GO:0010629 9.8 PTH MIR214 MIR140 IGF1 ESR1 BMP2
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.78 TNFSF11 LRP5 ESR1
7 osteoblast differentiation GO:0001649 9.76 SP7 RUNX2 BMP2 BGLAP
8 bone development GO:0060348 9.71 TNFSF11 LRP5 BGLAP
9 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.69 MIR214 MIR140 MIR133A1
10 positive regulation of osteoblast differentiation GO:0045669 9.67 RUNX2 LRP5 IGF1 BMP2
11 skeletal system development GO:0001501 9.65 RUNX2 PTH IGF1 BMP2 BGLAP
12 mammary gland alveolus development GO:0060749 9.6 TNFSF11 ESR1
13 positive regulation of ossification GO:0045778 9.59 PTH BMP2
14 positive regulation of glycogen biosynthetic process GO:0045725 9.58 PTH IGF1
15 regulation of osteoclast differentiation GO:0045670 9.58 TNFSF11 BGLAP
16 osteoblast development GO:0002076 9.58 RUNX2 LRP5 BGLAP
17 positive regulation of osteoblast proliferation GO:0033690 9.57 LRP5 BMP2
18 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.56 RUNX2 BMP2
19 bone mineralization involved in bone maturation GO:0035630 9.55 IGF1 BMP2
20 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.52 RUNX2 BMP2
21 bone resorption GO:0045453 9.26 TNFSF11 PTH CTSK ACP5
22 ossification GO:0001503 9.1 TNFSF11 SOST RUNX2 BMP2 BGLAP ACP5

Molecular functions related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR23A MIR214 MIR188 MIR140 MIR133A1

Sources for Bone Resorption Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....